Findings
Digital biomarkers, such as DaTscan enrichment and SV95C-like endpoints, can reduce sample sizes and improve study performance when used effectively.
Digital endpoints help address challenges in neurodegenerative disorder trials, such as variability in subjective outcome measures.
Quantifying the benefits of digital technologies in clinical trials supports stakeholder alignment and resource prioritization.
Current gaps include the lack of robust economic models, evidence for clinical impact, and standardized frameworks for biomarker integration.
A business-oriented, data-driven approach facilitates collaboration between pharmaceutical sponsors, technology providers, and regulatory bodies.

Recommendations
Develop quantified frameworks like Moneyball to simulate the impact of digital biomarkers on study performance metrics, including sample size and probability of success (PoSS).
Prioritize early alignment between biomarkers and therapeutic objectives to streamline validation and regulatory approval processes.
Build multi-stakeholder collaborations to address gaps in evidence requirements and create shared value frameworks for digital technology investments.
Enhance decision-making with real-time simulations of clinical trial scenarios to optimize patient selection and endpoint design.
Expand quantitative models to include diverse biomarker types, heterogeneous patient populations, and long-term treatment outcomes.

Regulatory Considerations
Align digital biomarker validation processes with the V3 framework (verification, analytical validation, clinical validation) to meet regulatory standards.
Demonstrate robust evidence of clinical utility and reproducibility to support regulatory submissions for novel digital endpoints.
Develop standardized protocols for integrating biomarkers into trial designs, ensuring compliance with EMA and FDA guidelines.
Address patient privacy and data security concerns in the use of wearable and digital health technologies.
Collaborate with regulatory bodies to establish frameworks for evaluating novel biomarker modalities and endpoints in clinical trials.